



Biotech Daily

Thursday October 15, 2026

Daily news on ASX-listed biotechnology companies

- * **ASX FLAT, BIOTECH DOWN: 4D MEDICAL UP 7%; IMPEDIMED DOWN 14%**
- * **WEHI: 'GAMMA DELTA T-CELLS KILL SMALL CELL LUNG CANCER'**
- * **BLS Q1 REVENUE UP 89% TO \$27m**
- * **MEDICAL DEVELOPMENTS Q1 REVENUE DOWN 6% TO \$10m**
- * **EPIMINDER ENROLS 100 OF 210 MINDER EPILEPSY STUDY PATIENTS**
- * **PARADIGM: 'NON-US DATA GOOD, MOST MISSING DATA FROM THE US'**
- * **NEUROSCIENTIFIC AGM BACKS 'MIRO SCIENCES' NAME CHANGE**
- * **PRESCIENT AGM DEFEATS 10% PLACEMENT CAPACITY**
- * **IMPEDIMED 110m M-D RIGHTS, 'SOZO HEALTH' NAME CHANGE AGM**
- * **ARTRYA 50% DIRECTOR FEE HIKE AGM**
- * **MEDICAL DEV LOSES CEO BRENT MACGREGOR; CFO TO CEO**

MARKET REPORT

The Australian stock market slipped 0.09 percent on Thursday October 15, 2026, with the ASX200 down 8.2 points to 8,719.7 points. Just four of the Biotech Daily Top 40 were up, 30 fell, five traded unchanged and one was untraded. The four Big Caps were mixed.

4D Medical was the best of the four, up 28 cents or 7.4 percent to \$4.08, with 4.9 million shares traded. Imricor climbed 5.1 percent; Aroa rose 2.9 percent; both CSL and Medical Developments were up 1.25 percent; with Resmed up by 0.03 percent.

Impedimed led the falls, down 0.1 cents or 14.3 percent to 0.6 cents, with 9.8 million shares traded. Artrya lost 10.1 percent; EBR was down 9.7 percent; Curvebeam, Immutep, Proteomics and Syntara were down eight percent or more; Actinogen, Botanix and Cyclopharm shed more than seven percent; Prescient and Starpharma were down more than six percent; Clarity, Imugene and Resonance fell more than five percent; Emvision and Lumos lost more than four percent; Clinuvel and Saluda were down more than three percent; Atomo, Mesoblast, Orthocell and Polynovo shed more than two percent; Alcidion, Avita, Micro-X, Neuren, Racura and Telix were down one percent or more; with Cochlear, Nanosonics and Pro Medicus down by less than one percent.

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says it has found 'gamma delta T-cells' can detect and kill small cell lung cancer cells, which may lead to additional treatment options.

WEHI said patients with higher levels of gamma delta T-cells "lived longer, uncovering a hidden immune defence that could be exploited to attack these hard-to-treat tumors".

The Institute said the researchers "showed existing drugs could be repurposed to boost the cancer-killing activity of these immune cells, opening new opportunities to strengthen current treatments and help more patients benefit from these therapies".

WEHI said the study, titled '[Gamma delta] T cells modulate anti-tumor immunity in small cell lung cancer' was published in Cancer Cell at: <https://bit.ly/4Bd1uNi>.

The Institute said the study used miniature tumors from donated patient samples through the Victorian Cancer Biobank with the Royal Melbourne Hospital.

WEHI said that when the researchers "combined the mini tumors with gamma delta T-cells taken from the patients' own blood, they found the immune cells were highly effective at recognizing and killing [small cell lung cancer] cells".

The Institute said the researchers discovered they could amplify the immune response by using the approved lung cancer therapy tarlatamab with the approved osteoporosis and cancer-related bone disease treatment zoledronate.

WEHI said zoledronate "increased the number of gamma delta T-cells available and enhanced their ability to recognize [small cell lung cancer] tumors ... [and] tarlatamab acted like a magnetic force that brought the immune cells into closer contact with the cancer".

WEHI said the drug combination "significantly enhanced the gamma delta T-cells' ability to attack the cancer cells, suggesting a potential new way to strengthen anti-cancer immunity in [small cell lung cancer]".

The Institute said it focused on gamma delta T cells after analyzing data from two trials which established immuno-therapy as a standard treatment for small cell lung cancer.

WEHI said researchers hoped to "translate the findings into a new class of immuno-therapy drugs for small cell lung cancer, in an ongoing collaboration with researchers at the Doherty Institute".

WEHI laboratory head and senior author Prof Kate Sutherland said the findings could help solve one of the field's most pressing questions, how to boost the number of lung cancer patients who respond to immuno-therapy.

"For decades, we've known that small cell lung cancer is exceptionally good at hiding from the immune system," Prof Sutherland said. "We've found an immune cell that appears to be able to see through that disguise."

"Strikingly, patients whose tumors contained more of these specialized immune cells often had better treatment outcomes," Prof Sutherland said.

"This is the strongest evidence yet that gamma delta T cells are present in small cell lung cancers and appear capable of fighting the disease," Prof Sutherland said.

"It suggests these cells may offer an alternative immune attack route for tumours that are able to evade conventional cancer-fighting immune cells, opening up new possibilities for treating a cancer that has seen few advances over the past decades," Prof Sutherland said.

Study first author Dr Jin Ng said that "the findings also raise the possibility of using existing gamma delta T-cells for adoptive transfer therapies, where large numbers of these immune cells are grown outside the body and infused back into patients".

"This could open an entirely new avenue for personalized treatment approaches in small cell lung cancer and other solid cancers that are often missed by conventional immune cells," Dr Ng said.

BLS PHARMACEUTICALS (FORMERLY BIOXYNE)

BLS says record revenue for the three months to September 30, 2026 was up 89.4 percent to \$26.7 million, compared to the previous corresponding period.

BLS said three-month customer receipts rose 73.3 percent to \$22,447,000 from sales and manufacturing of its medical marijuana, 3,4 methylene-dioxy-methamphetamine (MDMA) and psilocybin products, compared to the prior corresponding period.

The company said the result reflected “continued growth across the company’s Australian manufacturing operations and international supply platform, including ongoing supply into Germany, while BLS continues to invest in additional manufacturing capability in the UK”. The company said it reaffirmed its 2026-’27 full-year revenue guidance of between \$105 million to \$115 million in revenue, an increase of 42 percent to 55 percent on \$74.2 million in the year to June 30, 2026.

BLS said it was \$1,961,000 three-month, cash-flow positive, with cash and equivalents of \$12,710,000 at September 30, 2026 compared to \$4,543,000 the prior year.

BLS was unchanged at \$1.085.

MEDICAL DEVELOPMENTS

Medical Developments says revenue for the three months to September 30, 2026 fell 6.4 percent to \$10.2 million, compared to the prior corresponding period.

Medical Developments said receipts from customers were \$9.7 million for the three months, down 13.4 percent compared to the previous corresponding period, “reflecting lower Pentrox volumes”.

The company said Pentrox inhaled methoxyflurane analgesic sales fell 3.8 percent to \$7.6 million in the three months, with volumes in Australia up 10 percent “with solid demand from ambulance and continued growth in the Australian hospital segment”.

Medical Developments said volumes in Europe and the rest of the world were “lower, due to inventory stocking in the prior period, driven in part by transition to partner supply in France in July 2025”.

The company said respiratory revenue fell 13.3 percent to \$2.6 million, with sales in the US “generally in line with the [prior corresponding period] though revenue in Australia was down, impacted by a mild winter and lower occurrence of respiratory conditions”.

Medical Developments said it had a \$329,000 cash burn, with cash and cash equivalents of \$20,599,000 at September 30, 2026 compared to \$16,143,000 at September 30, 2025.

Medical Developments was up half a cent or 1.25 percent to 40.5 cents.

EPIMINDER

Epiminder says it has enrolled 100 of 210 participants in its randomized, controlled, blinded, multi-centre US study of the Minder system for drug-resistant epilepsy.

Earlier this year, Epiminder said the first of 210 drug-resistant epilepsy patients were implanted in a six-month trial of its Minder epilepsy monitor (BD: Jan 19, 2026).

Epiminder said the study was assessing whether its sub-scalp electro-encephalo-gram (EEG) monitoring with the Minder improved clinical decision-making for patients who had undergone prolonged monitoring without conclusive results.

The company said it expected enrolment to be completed by July 2027.

Epiminder chief executive officer Dr Rohan Hoare said reaching 100 patients in the study “ahead of the November target demonstrates strong momentum for Epiminder and is a clear reflection of the confidence US epileptologists have in the Minder system”.

Epiminder was up half a cent or 1.8 percent to 28.5 cents.

PARADIGM BIOPHARMACEUTICALS (ADMINISTRATORS APPOINTED)

Paradigm says further data analysis shows that non-US patients in its phase III trial had “statistically significant improvement in weekly average daily pain” ($p = 0.0007$).

Paradigm said 91 of 97 patients missing 112-day weekly average daily pain data at the interim analysis were in the US and the review identified a “number of factors affecting dosing, including laboratory delays”.

Last month, the company halted its 538-patient, phase III trial of injectable pentosan polysulfate sodium (PPS), or Zilosul, for knee osteoarthritis, citing the data safety monitoring board finding that the interim efficacy result “did not reach the pre-specified threshold required for the study to continue” (BD: Sep 23, 2026).

Last week, the company said missing data in the phase III trial was “more frequent at the US sites” (BD: Oct 9, 2026).

Today, Paradigm said non-US patients receiving PPS showed “statistically significant benefits in physical function ($p = 0.0026$), pain assessed using the [Western Ontario and McMaster Universities Osteoarthritis Index] questionnaire ($p = 0.0147$) and patients’ overall assessment of improvement ($p = 0.0032$) compared with placebo”.

The company said of the 114 non-US patients, 58 received PPS and 56 were dosed with placebo; and 95 patients (83.3%) had day-112 pain assessments available.

Paradigm said the administrators had “received notice that the former board is preparing a proposal to preserve the program”.

The company said no proposal had “yet been received or assessed, and any proposal will be considered alongside other options in the administration”.

Paradigm was in a suspension and last traded at 24.5 cents

NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says its annual general meeting has voted to change the company name to ‘Miro Sciences’ and ticker code to ‘MSX’.

Last month, Neuroscientific said the name change vote was a special resolution, effective from the date that the Australian Securities and Investments Commission (ASIC) altered the details of the company’s registration.

At the time, the company said the change “more accurately reflects the proposed future ambitions of the company following its acquisition of the Stemsart patented stem cell technology via its acquisition of Isopogen WA in June 2025” (BD: Jun 27, 2025).

Today, Neuroscientific said the change of company name was approved by 99.86 percent of the meeting, with the remaining resolutions passed with similar support.

Neuroscientific was up half a cent or 8.9 percent to 6.1 cents.

PRESCIENT THERAPEUTICS

Prescient says its annual general meeting defeated the special resolution to approve the 10 percent placement capacity with 27.77 percent of the vote against.

Prescient said the placement capacity was opposed by 28,509,957 votes (27.77%), with 74,168,427 votes (72.23%) in favor.

The company said the adoption of the remuneration report and re-election of Dr Ellen Feigl and Dr Gavin Shepherd as directors faced minor dissent.

According to its most recent notice, Prescient had 1,051,514,543 shares on issue, meaning that the votes against the placement capacity amounted to 2.7 percent of the company, not sufficient to requisition extraordinary general meeting.

Prescient fell 0.4 cents or 6.15 percent to 6.1 cents with 1.9 million shares traded.

IMPEDIMED

Impedimed says investors will vote to issue 109,794,161 performance rights to managing-director Erik Anderson and change the company name to 'Sozo Health'.

Impedimed said the performance rights were valued at \$1,097,942 and would be exercisable at no price within seven years from the grant date and would vest on share price related milestones.

The company said the rights were in addition to Mr Anderson's \$US350,000 (\$A503,600) annual fixed remuneration.

Impedimed said the change of name to 'Sozo Health Holdings Ltd' "more accurately describes the company's core business and better aligns with the company's product, strategy and vision".

The company said shareholders would vote to adopt the remuneration report, re-elect directors Janelle Delaney and Fiona Bones, issue securities under the employee incentive plan and approve Mr Anderson's termination benefits.

The meeting will be held online and at Level 24, Brookfield Place, 10 Carrington Street, Sydney on November 18, 2026 at 11am (AEDT).

Impedimed fell 0.1 cents or 14.3 percent to 0.6 cents with 9.8 million shares traded.

ARTRYA

Artrya says its annual general meeting will vote to increase the non-executive director aggregate fee pool by 50 percent from \$500,000 to \$750,000.

Artrya said the increase reflected "the increase in the number of directors from three to five, the doubling of North American directors with relevant clinical experience and ensures the company's ability to attract the skills required with an appropriate level of remuneration".

The company said shareholders would vote to adopt the remuneration report, elect Dr Jeffrey Le Benger, Helen Kurincic and Bernard Ridgeway as directors, issue securities under the employee incentive plan, renew the proportional takeover provisions in the constitution and amend the constitution.

The meeting will be held at 1257 Hay Street, West Perth on November 13, 2025 at 11.30am (AWST).

Artrya fell 29 cents or 10.1 percent to \$2.59 with 3.4 million shares traded.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says chief financial officer Anita James will serve as interim chief executive officer following Brent MacGregor stepping down.

Medical Developments said Mr MacGregor had advised the company of his intention to step down, with Ms James as an interim replacement effective from October 15, 2026, and Mr MacGregor to continue to support the company in an advisory capacity to provide continuity and ensure a smooth transition until November 15, 2026.

The company said Ms James' remuneration would remain unchanged at \$594,381 in fixed yearly remuneration, inclusive of short-term cash and equity incentives and other benefits.